Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables (2016 - 2023)

Ocular Therapeutix has reported Notes Payables over the past 9 years, most recently at $2.1 million for Q2 2023.

  • For Q2 2023, Notes Payables changed N/A year-over-year to $2.1 million; the TTM value through Jun 2023 reached $2.1 million, changed N/A, while the annual FY2020 figure was $8.3 million, N/A changed from the prior year.
  • Notes Payables for Q2 2023 was $2.1 million at Ocular Therapeutix, down from $8.3 million in the prior quarter.
  • Over five years, Notes Payables peaked at $8.3 million in Q4 2020 and troughed at $2.1 million in Q1 2020.
  • A 3-year average of $5.2 million and a median of $5.2 million in 2020 define the central range for Notes Payables.
  • On a YoY basis, Notes Payables climbed as much as 299.71% in 2021 and fell as far as 299.71% in 2021.
  • Year by year, Notes Payables stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then crashed by 74.87% to $2.1 million in 2023.
  • Business Quant data shows Notes Payables for OCUL at $2.1 million in Q2 2023, $8.3 million in Q1 2021, and $8.3 million in Q4 2020.